CMTL Comtech Telecommunications Corporation

Filed Pursuant to Rule 424(b)(3)

Registration No. 333-280839

PROSPECTUS 

 

Up to 1,435,884 shares of Common Stock underlying the Warrants

 

 

Comtech Telecommunications Corp.

 

This prospectus relates to the resale from time to time, by the selling stockholders (the “Selling Stockholders”) identified in this prospectus under the caption “Selling Stockholders,” of up to 1,435,884 shares of common stock (the “Warrant Shares”), par value $0.10 per share (the “Common Stock”), which the selling stockholders may acquire upon the exercise of outstanding warrants (the “Warrants”).

 

We issued the Warrants to the Selling Stockholders in a private placement concurrent with the entry into our Credit Facility (as defined herein). Each Warrant will have an exercise price of $0.10 per share of Common Stock. The Warrants will expire on or prior to the close of business on June 17, 2031.

 

The closing of the issuance and sale of the Warrants was consummated on June 17, 2024.

 

The Selling Stockholders of the securities and any of their pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their securities covered hereby on the principal trading market or any other stock exchange, market or trading facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices. See “Plan of Distribution” in this prospectus for more information. We will not receive any proceeds from the resale or other disposition of the Common Stock by the Selling Stockholders. However, we will receive the proceeds of any cash exercise of the Warrants. See “Use of Proceeds” beginning on page 8 and “Plan of Distribution” beginning on page 11 of this prospectus for more information.

 

Our Common Stock is listed on the Nasdaq Stock Market LLC under the symbol “CMTL.”

 

On July 22, 2024, the last reported sale price of our Common Stock was $3.09 per share.

 

Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 4 of this prospectus and under similar headings in the other documents that are incorporated by reference into this prospectus for a discussion of information that should be considered in connection with an investment in our securities.

 

Neither the Securities and Exchange Commission (the “SEC”) nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. The securities are not being offered in any jurisdiction where the offer is not permitted.

 

The date of this prospectus is July 23, 2024.

 

 

TABLE OF CONTENTS

 

Prospectus

 

		Page
About This Prospectus		1
Prospectus Summary		2
Risk Factors		4
Cautionary Note Regarding Forward-Looking Statements		6
Market, Industry And Other Data		8
Use of Proceeds		8
Market Price of Our Common Stock and Related Stockholder Matters		8
Private Placement of Warrants		9
Selling Stockholders		9
Plan of Distribution		11
Description of Capital Stock		12
Legal Matters		17
Experts		17
Where You Can Find Additional Information		18
Material Changes		18
Incorporation of Certain Information by Reference		18

 

 

About This Prospectus

 

You should rely only on the information provided in or incorporated by reference in this prospectus, or in a related free writing prospectus, or documents to which we otherwise refer you. We have not authorized anyone else to provide you with different information.

 

We have not authorized any dealer, agent or other person to give any information or to make any representation other than those contained or incorporated by reference in this prospectus or any related free writing prospectus. You must not rely upon any information or representation not contained or incorporated by reference in this prospectus or any related free writing prospectus. This prospectus and any related free writing prospectus, if any, do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus and any related free writing prospectus, if any, constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. You should not assume that the information contained in this prospectus and any related free writing prospectus, if any, is accurate on any date subsequent to the date set forth on the front of such document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus and any related free writing prospectus is delivered or securities are sold on a later date.

 

We have not done anything that would permit this offering or possession or distribution of this prospectus or any free writing prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You are required to inform yourself about and to observe any restrictions relating as to this offering and the distribution of this prospectus and any such free writing prospectus outside the United States.

 

We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference in this prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.

 

 

 

 

 

 

Risk Factors

 

Investing in our securities involves a high degree of risk. In addition to the other information included or incorporated by reference in this prospectus, you should carefully consider the risks described below and in the section titled “Risk Factors” in our Annual Report on Form 10-K for our most recent fiscal year filed with the SEC, subsequent Quarterly Reports on Form 10-Q, and in other reports we file with the SEC that are incorporated by reference herein, before making an investment decision. The risks and uncertainties described therein and below could materially adversely affect our business, operating results and financial condition, as well as cause the value of our securities to decline. You may lose all or part of your investment as a result. You should also refer to the other information contained in this prospectus or incorporated by reference herein, including our financial statements and the notes to those statements, and the information set forth under the caption “Cautionary Note Regarding Forward-Looking Statements.” Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks mentioned below. Forward-looking statements included in this prospectus are based on information available to us on the date hereof, and all forward-looking statements in documents incorporated by reference are based on information available to us as of the date of such documents. We disclaim any intent to update any forward-looking statements. The risks described below and contained in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q are not the only ones that we face. Additional risks not presently known to us or that we currently deem immaterial may also adversely affect our business operations.

 

Risks Relating to Our Common Stock and Other Securities:

 

There are a large number of shares of Common Stock underlying our outstanding Series B-1 Convertible Preferred Stock, stock-based awards issued to employees and Warrants, and the sale of these shares may depress the market price of our Common Stock and cause immediate and substantial dilution to our existing stockholders.

 

As of June 30, 2024, we had 28,493,857 shares of Common Stock issued and outstanding, outstanding shares of Series B-1 Convertible Preferred Stock convertible into 22,369,947 shares of Common Stock, outstanding stock-based awards convertible into 1,799,644 shares of Common Stock, and outstanding Warrants to purchase 1,435,884 shares of Common Stock. The issuance of shares upon conversion, vesting or exercise of these instruments will cause immediate and substantial dilution to our stockholders and any sale thereof may depress the market price of our Common Stock.

 

Our stock price is volatile.

 

The stock market in general and the stock prices of technology-based companies, in particular, experience extreme volatility that often is unrelated to the operating performance of any specific public company. The market price of our common stock has fluctuated significantly in the past and is likely to fluctuate significantly in the future as well. Factors that could have a significant impact on the market price of our stock include, among others:

 

·

strategic transactions, such as acquisitions and divestures by us and our competitors;

 

·

our ability to successfully integrate and manage recent acquisitions;

 

·

our issuance of potentially dilutive equity or equity-type securities;

 

·

our issuance of debt;

 

·

our ability to successfully access equity and debt capital markets;

 

·

future announcements concerning us or our competitors;

 

·

shareholder activism involving our common stock, board of directors (our “Board of Directors”) or corporate governance;

 

 

·

receipt or non-receipt of substantial orders for products and services;

 

·

quality deficiencies in services or products;

 

·

results of technological innovations and new commercial products;

 

·

changes in recommendations of securities analysts;

 

·

government regulations;

 

·

changes in the status or outcome of government audits;

 

·

proprietary rights or product or patent litigation;

 

·

changes in U.S. government policies;

 

·

changes in economic conditions generally, particularly in the terrestrial and wireless networks and satellite and space communications markets;

 

·

changes in securities market conditions, generally;

 

·

changes in prevailing interest rates;

 

·

changes in the status of litigation and legal matters (including changes in the status of export matters);

 

·

cyber attacks;

 

·

energy blackouts;

 

·

acts of terrorism or war;

 

·

inflation or deflation;

 

·

rumors or allegations regarding our financial disclosures or practices; and

 

·

potential resurgences of the COVID-19 or similar pandemics.

 

Shortfalls in our sales or earnings in any given period relative to the levels expected by securities analysts could immediately, significantly and adversely affect the trading price of our common stock.

 

Shares eligible for future sale may adversely affect our common stock price.

 

Sales of our Common Stock or other securities (including securities convertible into our Common Stock) in the public or private market, or the perception that these sales may occur, could cause the market price of our common stock to decline. This could also impair our ability to raise additional capital through the sale of our equity securities. Under our certificate of incorporation, we are authorized to issue up to 100,000,000 shares of common stock and 2,000,000 shares of preferred stock and we are authorized to convert our authorized preferred stock into common stock. We cannot predict the size of future issuances of our common stock or other securities or the effect, if any, that future sales and issuances of our common stock and other securities would have on the market price of our common stock.

 

 

Future issuances of our shares of common stock could dilute your ownership interest in Comtech and reduce the market price of our shares of common stock.

 

In addition to potential issuances of our shares of common stock associated with acquisitions, in the future, we may issue additional securities to raise capital. We may also acquire interests in other companies by using a combination of cash and our common stock or just our common stock. We may also issue securities convertible into, or exercisable for, our common stock. Any of these events may dilute a stockholder’s ownership interest in Comtech and have an adverse impact on the price of our common stock.

 

Cautionary Note Regarding Forward-Looking Statements

 

Certain statements contained or incorporated by reference in this prospectus are considered forward-looking statements (within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) concerning our business, results of operations, economic performance and/or financial condition, based on management’s current expectations, plans, estimates, assumptions, statements concerning the future of our industry, product development, business strategy, continued acceptance of our products, market growth, dependence on significant customers and projections.

 

Any statements contained or incorporated by reference in this prospectus that are not statements of historical fact may be deemed forward-looking statements.

 

Forward-looking statements can be identified by words such as: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “future,” “goal,” “outlook,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “strategy,” “target,” “will,” “would,” and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding our future performance and financial condition, plans to address our ability to continue as a going concern, plans and objectives of our management and our assumptions regarding such future performance, financial condition, and plans and objectives that involve certain significant known and unknown risks and uncertainties and other factors not under our control which may cause our actual results, future performance and financial condition, and achievement of our plans and objectives of our management to be materially different from the results, performance or other expectations implied by these forward-looking statements.

 

Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update any forward-looking statement in light of new information or future events, although we intend to continue to meet our ongoing disclosure obligations under the U.S. securities laws and other applicable laws. Forward-looking statements are subject to change and may be affected by risks and uncertainties and other factors, most of which are difficult to predict and are generally beyond our control. These factors include, among other things:

 

·

our ability to access capital and liquidity so that we are able to continue as a going concern;

 

·

our ability to successfully implement changes in our executive leadership;

 

·

the possibility that the expected synergies and benefits from acquisitions and/or restructuring activities will not be fully realized, or will not be realized within the anticipated time periods;

 

·

the risk that acquired businesses will not be integrated successfully;

 

·

the possibility of disruption from acquisitions or dispositions, making it more difficult to maintain business and operational relationships or retain key personnel;

 

·

the risk that we will be unsuccessful in implementing our “One Comtech” transformation and integration of individual businesses into two segments;

 

 

·

the risk that we will be unsuccessful in implementing a tactical shift in our Satellite and Space Communications segment away from bidding on large commodity service contracts and toward pursuing contracts for our niche products and solutions with higher margins;

 

·

the nature and timing of our receipt of, and our performance on, new or existing orders that can cause significant fluctuations in net sales and operating results;

 

·

the timing and funding of government contracts;

 

·

adjustments to gross profits on long-term contracts;

 

·

risks associated with international sales;

 

·

rapid technological change;

 

·

evolving industry standards;

 

·

new product announcements and enhancements;

 

·

changing customer demands and/or procurement strategies and our ability to scale opportunities and deliver solutions to current and prospective customers;

 

·

changes in prevailing economic and political conditions, including as a result of Russia’s military incursion into Ukraine, the Israel-Hamas war and attacks in the Red Sea region;

 

·

changes in the price of oil in global markets;

 

·

changes in prevailing interest rates and foreign currency exchange rates;

 

·

risks associated with our legal proceedings, customer claims for indemnification, and other similar matters;

 

·

risks associated with our obligations under our Credit Facility;

 

·

risks associated with our large contracts;

 

·

risks associated with supply chain disruptions; and

 

·

other risks, uncertainties and factors included or incorporated by reference in this prospectus, including those set forth under “Risk Factors” and those included under the heading “Risk Factors” in our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q.

 

Additional factors could cause our business outlook, actual financial condition or results to differ materially from those expressed in, or implied by, the forward-looking statements, and therefore you should not place too much reliance on them. These factors include, among others, those described herein, under “Risk Factors” in this prospectus and the risks described in our other filings with the SEC, including our Annual Report on Form 10-K, which are incorporated by reference in this prospectus.

 

It is not possible to predict or identify all such factors, and therefore the factors that are noted are not intended to be a complete discussion of all potential risks or uncertainties that may affect forward-looking statements. If these or other risks and uncertainties materialize, or if the assumptions underlying any of the forward-looking statements prove incorrect, our actual performance and future actions may be materially different from those expressed in, or implied by, such forward-looking statements.

 

 

Market, Industry And Other Data

 

Market data and certain industry data and forecasts used in, or incorporated by reference in, this prospectus were obtained from sources we believe to be reliable, including market research databases, publicly available information, reports of governmental agencies and industry publications and surveys. We have relied on certain data from third-party sources, including internal surveys, industry forecasts and market research, which we believe to be reliable based on our management’s knowledge of the industry. Forecasts are particularly likely to be inaccurate, especially over long periods of time. In addition, we do not necessarily know what assumptions regarding general economic growth were used in preparing the third-party forecasts we cite. Statements as to our market position are based on the most currently available data. While we are not aware of any misstatements regarding the industry data presented in this prospectus and the documents incorporated by reference into this prospectus, our estimates involve risks and uncertainties and are subject to change based on various factors, including those discussed under the heading “Risk Factors” in this prospectus and the documents incorporated by reference into this prospectus.

 

Use of Proceeds

 

We will not receive any proceeds from the sale of the Warrant Shares by the Selling Stockholders. However, we will receive proceeds from the exercise of the Warrants by the Selling Stockholders to the extent they are exercised for cash. We estimate that the maximum proceeds that we may receive from the exercise of the Warrants, assuming all the Warrants are exercised at their exercise price of $0.10, will be $143,588. We do not know, however, whether any of the Warrants will be exercised or, if any of the Warrants are exercised, when they will be exercised. It is possible that the Warrants will expire and never be exercised. There are circumstances under which the Warrants may be exercised utilizing net share settlement (“Net Share Settlement”). In these circumstances, even if the Warrants are exercised, we may not receive any proceeds, or the proceeds that we do receive may be significantly less than what we might expect. We intend to use the aggregate net proceeds from the exercise of the Warrants for general corporate purposes, including working capital. The Selling Stockholders will pay any expenses incurred by the Selling Stockholders for brokerage, accounting, tax or legal services or any other expenses incurred by the Selling Stockholders in disposing of its shares of Common Stock. We will bear all other costs, fees and expenses incurred in effecting the registration of the shares covered by this prospectus, including, without limitation, all registration fees and fees and expenses of our counsel and our accountants.

 

Market Price of Our Common Stock and Related Stockholder Matters

 

Market Information

 

Our Common Stock is listed on The Nasdaq Stock Market LLC under the symbol “CMTL.” A description of our Common Stock is set forth under the heading “Description of Capital Stock” beginning on page 12 of this prospectus.

 

The last reported sale price for our Common Stock on July 22, 2024 was $3.09 per share.

 

Holders

 

As of June 30, 2024, we had approximately 323 record holders of our Common Stock and 9 record holders of our Series B-1 Convertible Preferred Stock. The number of record holders was determined from the records of our transfer agent and does not include beneficial owners of our Common Stock whose shares are held in the names of various security brokers, dealers, and registered clearing agencies. The transfer agent of our Common Stock is Equiniti Trust Company, LLC. The transfer agent and registrar’s address is 6201 15th Ave, Brooklyn, NY 11219.

 

Dividend Policy

 

During the third quarter of fiscal 2023, our Board of Directors, together with management, adjusted the Company’s capital allocation plans and determined to forgo a common stock dividend, thereby increasing our financial flexibility. Future common stock dividends, if any, remain subject to compliance with financial covenants under our Credit Facility, as well as approval from our Board of Directors and certain voting rights of holders of our Series B-1 Convertible Preferred Stock.

 

 

Private Placement of Warrants

 

On June 17, 2024, the Company entered into a Credit Agreement, dated as of June 17, 2024, among Comtech Telecommunications Corp., the lenders party thereto, TCW Asset Management Company LLC, as agent, and Wingspire Capital LLC, as revolving agent (the “Credit Facility”). The Credit Facility provides a senior secured loan facility consisting of: (i) a $162.0 million term loan and (ii) an asset-based revolving credit facility with revolving commitments in an aggregate principal amount of $60.0 million, which is subject to certain borrowing base limitations.

 

In connection with the Credit Facility, the Company issued the Warrants to the Selling Stockholders, which entitle the Selling Stockholders to purchase from the Company 1,435,884 shares of the Common Stock, at any time and from time to time after June 17, 2024 and on or prior to the close of business on June 17, 2031 (the “Expiration Date”), at an exercise price of $0.10 per share, subject to certain adjustments. The Warrants are exercisable until the Expiration Date, at the election of the holder, either in full or in part, for cash or by Net Share Settlement.

 

Upon a refinancing resulting in the payment in full of all Term Loan Obligations (as defined in the Credit Facility) on or before the relevant maturity date, each of the Selling Stockholders shall have the right (a “Put Right”) to sell, and, upon exercise by any Selling Stockholder of its Put Right, the Company shall have the obligation to purchase for cash, up to 50% of the Warrants held by such Selling Stockholder at a price per share equal to 90% of the 30-day volume-weighted average price of the Common Stock calculated as of the date of exercise of the Put Right.

 

Pursuant to the terms of the Warrants, we agreed to file a registration statement providing for the resale by the Selling Stockholders of the Warrant Shares within 30 calendar days from the date of the issuance of the Warrants. We agreed to use commercially reasonable efforts to cause such registration statement to become effective as soon as practicable thereafter and to keep such registration statement continuously effective until the earlier of (1) the date that the respective Selling Stockholder no longer owns any Warrants or Warrant Shares and (2) the date on which all Warrant Shares held by a holder may be sold pursuant to Rule 144 without regard to any volume or manner of sale restrictions, assuming all Warrants held by such holder are exercised on a Net Share Settlement basis.

 

Selling Stockholders

 

The Common Stock being offered by the Selling Stockholders are those issuable to the Selling Stockholders, upon exercise of the Warrants. For additional information regarding the issuances of the Warrants, see “Private Placement of Warrants” above. We are registering the Warrant Shares in order to permit the Selling Stockholders to offer the shares for resale from time to time. In addition to entering into the Credit Facility with us and the ownership of the shares of Common Stock and the Warrants, the Selling Stockholders have not had material relationships with us within the past three years.

 

The table below lists the Selling Stockholders and other information regarding the beneficial ownership of the shares of Common Stock by each of the Selling Stockholders. The second column lists the number of shares of Common Stock beneficially owned by each Selling Stockholder, based on its ownership of the shares of Common Stock and, as of June 30, 2024, assuming exercise of the Warrants held by the Selling Stockholders on that date. The third and fourth columns assume the sale of all Warrant Shares offered by the Selling Stockholders pursuant to this prospectus. The third column lists the Warrant Shares offered by this prospectus by the Selling Stockholders.

 

 

In accordance with the terms of the Warrants, this prospectus generally covers the resale of the maximum number of Warrant Shares issuable upon exercise of the Warrants. The Selling Stockholder may sell all, some or none of their shares in this offering. See “Plan of Distribution.”

 

Name of Selling Stockholders		Shares Owned prior to Offering(1)				Shares Offered by this Prospectus(2)				Shares Owned after Offering				Percentage of Shares Beneficially Owned after Offering(3)
Clover Private Credit Opportunities Origination II LP(4)			111,237				111,237				—				—
Clover Private Credit Opportunities Origination (Levered) II LP(5)			95,548				95,548				—				—
Maple Hill, LLC(6)			265,904				265,904				—				—
TCW Rescue Financing Fund II LP(7)			726,806				726,806				—				—
Trifolium O SPE LLC(8)			236,389				236,389				—				—

 

(1)

Represents Warrants to purchase up to an aggregate amount of 1,435,884 shares of Common Stock.

 

(2)

Represents Warrant Shares issuable upon exercise of the Warrants as of June 30, 2024.

 

(3)

Percentages are based on 28,493,857 shares of Common Stock outstanding as of June 30, 2024.

 

(4)

Consists of 111,237 Warrant Shares underlying Warrants issued on June 17, 2024. The securities are directly held by Clover Private Credit Opportunities Origination II LP, a Delaware limited partnership. UBS Asset Management (Americas) LLC (“UBS Asset Management”) is the investment manager of Clover Private Credit Opportunities Origination II LP and accordingly has voting control and investment discretion over the securities described herein held by the fund. Baxter Wasson and Rodrigo Trelles (“Mr. Wasson” and “Mr. Trelles”), co-Managing Directors of Clover Private Credit Opportunities Origination II LP, also have voting control and investment discretion over the securities described herein held by Clover Private Credit Opportunities Origination II LP. As a result, each of UBS Asset Management and Mr. Wasson and Mr. Trelles may be deemed to have beneficial ownership (as determined under Section 13(d) of the Exchange Act) of the securities described herein held by Clover Private Credit Opportunities Origination II LP. The address of Clover Private Credit Opportunities Origination II LP is c/o UBS Asset Management (Americas) LLC, as investment manager, One North Wacker Drive, 31st Flr, Chicago, IL 60606.

 

(5)

Consists of 95,548 Warrant Shares underlying Warrants issued on June 17, 2024. The securities are directly held by Clover Private Credit Opportunities Origination (Levered) II LP, a Delaware limited partnership. UBS Asset Management (Americas) LLC (“UBS Asset Management”) is the investment manager of Clover Private Credit Opportunities Origination (Levered) II LP and accordingly has voting control and investment discretion over the securities described herein held by the fund. Baxter Wasson and Rodrigo Trelles (“Mr. Wasson” and “Mr. Trelles”), co-Managing Directors of Clover Private Credit Opportunities Origination (Levered) II LP, also have voting control and investment discretion over the securities described herein held by Clover Private Credit Opportunities Origination (Levered) II LP. As a result, each of UBS Asset Management and Mr. Wasson and Mr. Trelles may be deemed to have beneficial ownership (as determined under Section 13(d) of the Exchange Act) of the securities described herein held by Private Credit Opportunities Origination (Levered) II LP. The address of Clover Private Credit Opportunities Origination (Levered) II LP is c/o UBS Asset Management (Americas) LLC, as investment manager, One North Wacker Drive, 31st Flr, Chicago, IL 60606.

 

(6)

Consists of 265,904 Warrant Shares underlying Warrants issued on June 17, 2024. The securities are directly held by Maple Hill, LLC, a Kansas limited liability company. The address of Maple Hill, LLC is 1 SW Security Benefit Place, Topeka, KS 66636.

 

(7)

Consists of 726,806 Warrant Shares underlying Warrants issued on June 17, 2024. The securities are directly held by TCW Rescue Financing Fund II LP, a Delaware limited partnership. The address of TCW Rescue Financing Fund II LP is 515 South Flower Street, Los Angeles, CA 90071.

 

(8)

Consists of 236,389 Warrant Shares underlying Warrants issued on June 17, 2024. The securities are directly held by Trifolium O SPE LLC, Delaware limited liability company. UBS Asset Management (Americas) LLC (“UBS Asset Management”) is the investment manager of Trifolium O SPE LLC and accordingly has voting control and investment discretion over the securities described herein held by the fund. Baxter Wasson and Rodrigo Trelles (“Mr. Wasson” and “Mr. Trelles”), co-Managing Directors of Trifolium O SPE LLC, also have voting control and investment discretion over the securities described herein held by Trifolium O SPE. As a result, each of UBS Asset Management and Mr. Wasson and Mr. Trelles may be deemed to have beneficial ownership (as determined under Section 13(d) of the Exchange Act) of the securities described herein held by Trifolium O SPE. The address of Trifolium O SPE LLC is c/o UBS Asset Management (Americas) LLC, as investment manager, One North Wacker Drive, 31st Flr, Chicago, IL 60606.

 

 

Plan of Distribution

 

Each Selling Stockholder and any of their pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their securities covered hereby on the principal trading market or any other stock exchange, market or trading facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices. A Selling Stockholder may use any one or more of the following methods when selling securities:

 

·

ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;

 

·

block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction;

 

·

purchases by a broker-dealer as principal and resale by the broker-dealer for its account;

 

·

an exchange distribution in accordance with the rules of the applicable exchange;

 

·

privately negotiated transactions;

 

·

settlement of short sales;

 

·

in transactions through broker-dealers that agree with the Selling Stockholders to sell a specified number of such securities at a stipulated price per security;

 

·

through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;

 

·

a combination of any such methods of sale; or

 

·

any other method permitted pursuant to applicable law.

 

The Selling Stockholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act, if available, rather than under this prospectus.

 

Broker-dealers engaged by the Selling Stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown in compliance with FINRA Rule 2121.

 

If at the time of any offering made under this prospectus a member of FINRA participating in the offering has a “conflict of interest” as defined in FINRA Rule 5121 (“Rule 5121”), that offering will be conducted in accordance with the relevant provisions of Rule 5121.

 

Our Common Stock is listed the Nasdaq Stock Market LLC under the symbol “CMTL.”

 

 

In connection with the sale of the securities or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The Selling Stockholders may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).

 

The Selling Stockholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be “underwriters” within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Each Selling Stockholder has informed the Company that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the securities.

 

The Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the securities. The Company has agreed to indemnify the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.

 

We agreed to keep this prospectus effective until the earlier of (a) the date that no Selling Stockholder owns any resale securities covered hereby and (b) the date on which all of the resale securities may be sold pursuant to Rule 144 without regard to any volume or manner of sale restrictions. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.

 

Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in market making activities with respect to the Common Stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the Selling Stockholders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the Common Stock by the Selling Stockholders or any other person. We will make copies of this prospectus available to the Selling Stockholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act).

 

Description of Capital Stock

 

The following description of our capital stock is intended as a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to our Restated Certificate of Incorporation (which we refer to as our “charter”), our Certificate of Designations of the Series B-1 Convertible Preferred Stock (the “Certificate of Designations”), our Third Amended and Restated By-Laws (the “Bylaws”), and to the applicable provisions of the Delaware General Corporation Law (the “DGCL”). Each of the charter, the Certificate of Designations and the Bylaws are included as an exhibit to the Registration Statement on Form S-1 of which this prospectus forms a part. Because the following is only a summary, it does not contain all of the information that may be important to you. For a complete description, you should refer to the charter, the Certificate of Designations and the Bylaws.

 

General

 

Our charter authorizes 100,000,000 shares of common stock, $0.10 par value per share, and 2,000,000 shares of preferred stock, $0.10 par value per share.

 

Common Stock

 

Common Stock Outstanding. As of June 30, 2024, we had 28,493,857 shares of Common Stock issued and outstanding.

 

Voting Rights. Each holder of our Common Stock is entitled to one vote for each share of Common stock on all matters submitted to a vote of stockholders.

 

Dividend Rights. Holders of our Common Stock are entitled to receive, as and when declared by our Board of Directors, dividends payable either in cash or in property, including securities of our Company, out of assets of our Company that are legally available therefor.

 

Rights upon Liquidation. Holders of our Common Stock are entitled to share pro rata, upon any liquidation, dissolution or winding up of our Company, in all remaining assets available for distribution to stockholders after payment of or provision for our liabilities and the liquidation preference of any of our outstanding preferred stock.

 

Preemptive Rights. Holders of our Common Stock have no preemptive rights to purchase, subscribe for or otherwise acquire any unissued or treasury shares or other securities.

 

Preferred Stock

 

As discussed in more detail below, we are authorized under our charter to issue up to 2,000,000 shares of preferred stock. We have currently designated two series of our preferred stock: (1) 200,000 shares of our preferred stock designated as Series A Junior Participating Cumulative Preferred Stock, none of which are outstanding, and (2) Series B-1 Convertible Preferred Stock, 171,827.05 shares of which are currently outstanding.

 

Blank Check Preferred Stock. Under our charter, our Board of Directors has the authority, without stockholder approval, to designate one or more series of preferred stock, to issue shares of preferred stock in such series up to the maximum number of shares of the relevant series of preferred stock authorized, and to determine the preferences, rights, privileges, qualifications, restrictions and limitations of any such series, including the number of shares constituting any such series and the designation of such series, dividend rights, voting rights, the rights and terms of conversion, the rights and terms of redemption, the terms of any sinking fund, retirement fund or purchase fund to be provided with such series and liquidation preferences. Acting under this authority, our Board of Directors could designate and issue a series of preferred stock with preferences, rights, privileges, qualifications, restrictions or limitations, and adopt a stockholder rights plan, having the effect of discriminating against an existing or prospective holder of securities as a result of such stockholder beneficially owning or commencing a tender offer for a substantial amount of our common stock. One of the effects of authorized but unissued and unreserved shares of capital stock may be to render more difficult or discourage an attempt by a potential acquirer to obtain control of our Company by means of a merger, tender offer, proxy contest or otherwise, and thereby protect the continuity of the Company’s management. The issuance of such shares of capital stock may have the effect of delaying, deferring or preventing a change in control of the Company without any further action by our stockholders. We have no present intention to adopt a stockholder rights plan, but could do so without stockholder approval at any future time.

 

Series A Junior Participating Cumulative Preferred Stock. As of the date of this prospectus, we have designated 200,000 shares of our preferred stock as Series A Junior Participating Cumulative Preferred Stock, par value $0.10 per share, none of which are outstanding.

 

Series B-1 Convertible Preferred Stock. As of the date of this prospectus, we have designated 171,827.05 shares of our preferred stock as Series B-1 Convertible Preferred Stock, par value $0.10 per share, and currently have 171,827.05 of such shares outstanding.

 

 

Designation of Series B-1 Convertible Preferred Stock.

 

The Series B-1 Convertible Preferred Stock ranks senior to the shares of the Common Stock, with respect to the payment of dividends and the distribution of assets upon a liquidation, dissolution or winding up of the Company. As of June 17, 2024, the liquidation preference of the Series B-1 Convertible Preferred Stock was $178,112,483.49. Holders of the Series B-1 Convertible Preferred Stock will be entitled to a cumulative dividend (the “Dividend”) at the rate of 9.00% per annum, compounding quarterly, paid-in-kind, or 7.75% per annum, compounding quarterly, paid in cash, at the Company’s election. For any quarter in which the Company elects not to pay the Dividend in cash with respect to a share of Series B-1 Convertible Preferred Stock, such Dividend will become part of the liquidation preference of such share, as set forth in the Certificate of Designations. In addition, no dividend or other distribution on the Common Stock will be declared or paid on the Common Stock unless, at the time of such declaration and payment, an equivalent dividend or distribution is declared and paid on the Series B-1 Convertible Preferred Stock (the “Participating Dividend”), provided that in the case of any such dividend in the form of cash, in lieu of a cash payment, such Participating Dividend will become part of the liquidation preference of the shares of Series B-1 Convertible Preferred Stock, as set forth in the Certificate of Designations.

 

Conversion Rights and Mandatory Redemption.

 

The Series B-1 Convertible Preferred Stock is convertible into shares of Common Stock at the option of the holders thereof at any time. At any time after July 22, 2027, the Company has the right to mandatorily convert the Series B-1 Convertible Preferred Stock, subject to certain restrictions based on the price of the Common Stock in the preceding thirty (30) consecutive trading days. The conversion price for the shares of Series B-1 Convertible Preferred Stock is $7.99 as of the date hereof, subject to certain adjustments set forth in the Certificate of Designations (as adjusted, the “Conversion Price”).

 

Voting and Consent Rights.

 

Holders of the Series B-1 Convertible Preferred Stock are entitled to vote with the holders of the Common Stock on an as-converted basis. Holders of the Series B-1 Convertible Preferred Stock are entitled to a separate class vote with respect to, among other things, amendments to the Company’s organizational documents that have an adverse effect on the Series B-1 Convertible Preferred Stock, authorizations or issuances of securities of the Company (other than the issuance of, in the aggregate, up to $50,000,000 of shares of Common Stock in qualified offerings), the payment of dividends, related party transactions, repurchases or redemptions of securities of the Company, dispositions of businesses or assets, the incurrence of indebtedness and amendments to the Credit Facility on terms and conditions that, taken as a whole, (A) are materially different from the existing Credit Facility or (B) adversely affect the ability of the Company to perform its obligations in connection with an optional repurchase of the Series B-1 Convertible Preferred Stock, in each case, subject to the exceptions and qualifications set forth in the Certificate of Designations.

 

Repurchase Rights.

 

Each holder of Series B-1 Convertible Preferred Stock will have the right to require the Company to repurchase its shares of Series B-1 Convertible Preferred Stock either (a) on or after October 31, 2028 or (b) upon the consummation of an Asset Sale (as defined in the Certificate of Designations) meeting certain criteria, in either case, at a price and on the terms set forth in the Certificate of Designations. The Company will have the right to repurchase all, or less than all, of the shares of Series B-1 Convertible Preferred Stock upon the consummation of an Asset Sale meeting the same criteria, at a price and on the terms set forth in the Certificate of Designations.

 

In addition, each holder of Series B-1 Convertible Preferred Stock will have the right to cause the Company to repurchase its shares of Series B-1 Convertible Preferred Stock in connection with a Change of Control (as defined in the Certificate of Designations), at a price and on the terms set forth in the Certificate of Designations.

 

Right to Nominate Director.

 

For so long as the initial investors (the “Investors”) (or their permitted transferees) own beneficially and of record an amount of Series B-1 Convertible Preferred Stock with an aggregate liquidation preference equal to at least $25,000,000 (including the liquidation preference of any shares of Series B-1 Convertible Preferred Stock previously held that were subsequently converted into shares of common stock for so long as the Investors (or their permitted transferees) continue to own beneficially and of record such shares of common stock), the Investors representing at least a majority of the outstanding shares of Series B-1 Convertible Preferred Stock then outstanding have the right to nominate one person to serve on the Board of Directors (such nominee, the “Series B-1 Convertible Preferred Stock Nominee”, and such director, the “Series B-1 Convertible Preferred Stock Director”). For so long as the right to nominate one person to serve on the Board of Directors continues to be satisfied based on conditions outlined above, the Company shall nominate the Series B-1 Convertible Preferred Stock Nominee for election (or re-election, as applicable) as a director at the end of each term of the Preferred Stock Director as part of the slate proposed by the Company that is included in the proxy statement (or consent solicitation or similar document) of the Company relating to the election of the Board of Directors.

 

 

Standstill.

 

Until the earliest to occur of (a) January 22, 2025, with respect to clause (2) below and, otherwise, January 22, 2026, (b) the occurrence of an Insolvency Proceeding (as defined in the Credit Facility) and (c) certain Events of Default (as defined in the Credit Facility), subject to certain qualifications, the Investors will be subject to certain standstill restrictions pursuant to which the Investors will be restricted, among other things and subject to certain customary exceptions, from (1) acquiring more than a specified amount of the Company’s outstanding Common Stock or securities exchangeable for or convertible into the Common Stock, (2) entering into any derivative or other convertible instruments, hedging contracts or other derivative securities or similar instruments related to the purchase or sale of Common Stock, (3) making, participating in or encouraging any proxy solicitation or submitting any shareholder proposal to the Company, (4) publicly proposing any change of control or other material transaction involving the Company, (5) encouraging or entering into any agreements with any person with respect to any of the foregoing, (6) purchasing, selling or otherwise trading debt securities of the Company if as a result such Investor would beneficially own 19.99% of the Company’s outstanding debt securities or (7) taking any action that would require the Company to make a public announcement regarding any of the foregoing.

 

Transfer Restrictions.

 

Until the earlier of (a) January 22, 2025 and (b) termination of the standstill provisions (as described above), the Investors will be restricted from transferring the Series B-1 Convertible Preferred Stock, subject to certain specified exceptions.

 

Warrants

 

As of the date of this prospectus, we have outstanding 1,435,884 Warrants to purchase an aggregate of 1,435,884 shares of Common Stock.

 

Duration and Exercise

 

The Warrants will have an exercise price of $0.10 per share of Common Stock and are exercisable at any time and from time to time after June 17, 2024 and on or prior to the close of business on June 17, 2031. The Warrants are exercisable, at the election of the holder, either in full or in part, for cash or by Net Share Settlement. The exercise price is subject to adjustment in connection with (i) stock splits, dividends or distributions or other similar transactions, (ii) the issuance of rights or warrants to holders of the Common Stock, and (iii) any distributions of assets, including cash, stock or other assets or property, to holders of the Common Stock.

 

Liquidity Event

 

In connection with any recapitalization, reorganization, reclassification, consolidation, merger, or other transaction, which, in each case, is effected in such a way that all of the holders of Common Stock are entitled to receive consideration with respect to or in exchange for Common Stock (other than a transaction that triggers an adjustment) (a “Liquidity Event”), each Warrant holder will have the right to receive, upon exercise of such Warrants, such consideration as would have been issued or payable in such Liquidity Event (if such Warrant holder had exercised such Warrant immediately prior to such Liquidity Event) with respect to or in exchange, as applicable, for the number of Common Stock that would have been issued upon exercise of such Warrants, if such Warrants had been exercised immediately prior to the occurrence of such Liquidity Event.

 

 

Repurchase Right

 

Upon a refinancing resulting in the payment in full of all relevant obligations on or before the relevant maturity date, each of the Selling Stockholders shall have the right (a “Put Right”) to sell, and, upon exercise by any Selling Stockholder of its Put Right, the Company shall have the obligation to purchase for cash, up to 50% of the Warrants held by such Selling Stockholder at a price per share equal to 90% of the 30-day volume-weighted average price of the Common Stock calculated as of the date of exercise of the Put Right.

 

Transferability

 

In accordance with the terms of the Warrants and subject to certain registration requirements, a Warrant may be transferred at the option of the holder.

 

Fractional Shares

 

No fractional Warrant Shares, or scrip of any fractional Warrant Shares, will be issued upon the exercise of the Warrants. If any fraction of a share of Common Stock be issuable on the exercise of any Warrant, the holder will be entitled to receive a cash payment equal to the Market Price (as defined in the Warrant) less the exercise price of such fractional share.

 

Trading Market

 

There is no established trading market for the Warrants, and we do not expect a market to develop. We do not intend to apply for a listing for the Warrants on any securities exchange or other nationally recognized trading system. Without an active trading market, the liquidity of the Warrant will be limited.

 

Rights as a Shareholder

 

Except as otherwise provided in the Warrants or by virtue of the holders’ ownership of shares of Common Stock, the holders of Warrants do not have the rights or privileges of holders of our shares of Common Stock, including any voting rights, until such Warrant holders exercise their warrants.

 

Registration Rights

 

Pursuant to the terms of the Warrants, we agreed to file a registration statement providing for the resale by the Selling Stockholders of the Warrant Shares within 30 calendar days from the date of the issuance of the Warrants. We agreed to use commercially reasonable efforts to cause such registration statement to become effective as soon as practicable thereafter and to keep such registration statement continuously effective until the earlier of (1) the date that the respective Selling Stockholder no longer owns any Warrants or Warrant Shares and (2) the date on which all Warrant Shares held by a holder may be sold pursuant to Rule 144 without regard to any volume or manner of sale restrictions, assuming all Warrants held by such holder are exercised on a Net Share Settlement basis.

 

Certain Provisions of Delaware Law

 

We are subject to the provisions of Section 203 of the DGCL, an anti-takeover law. In general, Section 203 of the DGCL provides that, except in certain limited circumstances, a corporation shall not engage in any “business combination” with an “interested stockholder” for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. A “business combination” includes mergers, asset sales and other transactions resulting in a financial benefit to the interested stockholder. Subject to certain exceptions, for purposes of Section 203 of the DGCL, an “interested stockholder” is a person who, together with affiliates, owns, or within three years did own, 15% or more of the corporation’s voting stock. This provision could have the effect of delaying or preventing a change in control of our Company.

 

 

Liability of Directors and Officers

 

As permitted by Delaware law, our charter contains a provision that eliminates the personal liability of the directors to us and our stockholders for monetary damages for breaches of fiduciary duties as directors, except that such provision does not apply to any breach that involves:

 

	·	a breach of a director’s duty of loyalty to our company;
	·	any act or omission not in good faith or which involves intentional misconduct or a knowing violation of law;
	·	a transaction from which the director derives an improper personal benefit; or
	·	the payment of dividends or the approval of stock repurchases or redemptions that are unlawful under the DGCL.

 

Our by-laws provide that we shall indemnify (a) any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of our company) by reason of the fact that he is or was one of our directors, officers or employees, or is or was serving at our request as a director, officer or employee of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement, actually and reasonably incurred by him or her in connection with such action, suit or proceeding, provided such person acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was illegal, and (b) any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by us or in our name to procure a judgment in its favor by reason of the fact that he or she is or was one of our directors, officers or employees, or is or was serving at our request as a director, officer or employee of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees) actually and reasonably incurred by him or her in connection with the defense or settlement of such action or suit if he or she acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests and except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable for negligence or misconduct in the performance of his or her duty to us unless and only to the extent that the Court of Chancery of Delaware or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery of Delaware or such other court shall deem proper.

 

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the issuer pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

 

Legal Matters

 

The validity of the issuance of our securities offered in this prospectus will be passed upon for us by Paul, Weiss, Rifkind, Wharton & Garrison LLP, New York, New York.

 

Experts

 

The financial statements and the related financial statement schedule of Comtech Telecommunications Corp. as of July 31, 2023 and 2022, and for each of the three years in the period ended July 31, 2023, incorporated by reference in this Registration Statement and the effectiveness of Comtech Telecommunications Corp.’s internal control over financial reporting have been audited by Deloitte & Touche LLP, an independent registered public accounting firm, as stated in their reports. Such financial statements and financial statement schedule are incorporated by reference in reliance upon the reports of such firm given their authority as experts in accounting and auditing.

 

 

Where You Can Find Additional Information

 

We have filed with the SEC a Registration Statement on Form S-1 under the Securities Act with respect to the securities offered by this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement, as permitted by the rules and regulations of the SEC. For further information with respect to us and our securities, we refer you to the registration statement, including the exhibits filed as a part of the registration statement. Statements contained in this prospectus concerning the contents of any contract or any other document are not necessarily complete. If a contract or document has been filed as an exhibit to the registration statement, please see the copy of the contract or document that has been filed. Each statement in this prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. The SEC also maintains an Internet website that contains the registration statement of which this prospectus forms a part, as well as the exhibits thereto. These documents, along with future reports, proxy statements and other information about us, are available at the SEC’s website, www.sec.gov.

 

We are subject to the information and reporting requirements of the Exchange Act, and, in accordance with this law, file periodic reports and other information with the SEC. These periodic reports and other information are available at the SEC’s website, www.sec.gov. We also maintain a website at www.comtech.com. You may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. Information contained on our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is an inactive textual reference only.

 

Material Changes

 

None.

 

Incorporation of Certain Information by Reference

 

The SEC allows us to “incorporate by reference” into this prospectus the information in documents we file with it, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be a part of this prospectus. Any statement contained in any document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in or omitted from this prospectus or any accompanying prospectus supplement modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus.

 

We incorporate by reference the documents listed below; provided, however, we are not incorporating by reference any information furnished (but not filed) under Item 2.02 or Item 7.01 of any Current Report on Form 8-K:

 

·

Our Annual Report on Form 10-K for the fiscal year ended July 31, 2023 filed with the SEC on October 12, 2023.

 

·

Our Quarterly Reports on Form 10-Q for the three month periods ended (i) April 30, 2024, as filed with the SEC on June 18, 2024, (ii) January 31, 2024, as filed with the SEC on March 18, 2024 (as amended on March 22, 2024) and (iii) October 31, 2023, as filed with the SEC on December 7, 2023.

 

·

Our Current Reports on Form 8-K filed with the SEC on August 28, 2023, November 7, 2023, December 14, 2023, December 18, 2023 (as amended on December 22, 2023), January 9, 2024, January 22, 2024, January 23, 2024, March 13, 2024, March 15, 2024, April 1, 2024, May 2, 2024, June 18, 2024.

 

·

Our Definitive Proxy Statement on Schedule 14A, filed with the SEC on November 16, 2023, and the accompanying additional proxy materials filed with the SEC on December 5, 2023.

 

 

Upon written or oral request, we will provide without charge to each person, including any beneficial owner, to whom a copy of the prospectus is delivered a copy of the documents incorporated by reference in this prospectus (other than exhibits to such documents unless such exhibits are specifically incorporated by reference in this prospectus). You may request a copy of these filings, at no cost, by writing or telephoning us at the following address: Comtech Telecommunications Corp., 305 N 54th Street, Chandler, Arizona 85226, c/o Investor Relations, telephone: (480) 333-2200. You may also access these documents on our website at www.comtech.com.

 

Information on our website, including subsections, pages, or other subdivisions of our website, or any website linked to by content on our website, is not part of this prospectus and you should not rely on that information unless that information is also in this prospectus or incorporated by reference in this prospectus.

 

 

Up to 1,435,884 shares of Common Stock underlying the Warrants

 

 

 

 

 

Comtech Telecommunications Corp.

 

 

PROSPECTUS

 

 

July 23, 2024

 

 

---